BTAI Bioxcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.

$22.81  +1.86 (8.88%)
As of 12/07/2021 12:45:52 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/08/2018
Outstanding shares:  27,980,345
Average volume:  400,269
Market cap:   $600,458,204
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    09075P105
ISIN:        US09075P1057
Sedol:      BF4VBS8
Valuation   (See tab for details)
PE ratio:   -5.75
PB ratio:   2.39
PS ratio:   0.00
Return on equity:   -41.49%
Net income %:   -250,835.65%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy